Yes-associated protein-1 overexpression in ocular surface squamous neoplasia; a potential diagnostic marker and therapeutic target.
Zambia
invasive OSSN
ocular surface squamous neoplasia (OSSN)
preinvasive OSSN
yes-associated protein-1 (YAP-1)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
04
2023
accepted:
20
06
2023
medline:
21
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Yes-associated protein-1 (YAP-1) is a Hippo system transcription factor, which serves as an oncogene in squamous cell carcinoma, and several solid tumors when the Hippo pathway is dysregulated. Yet, the activity of YAP-1 in ocular surface squamous neoplasia (OSSN) has not been determined. Here, we investigate the relationship between YAP-1 overexpression and OSSN. Using a cross-sectional study design, we recruited 227 OSSN patients from the University Teaching Hospitals in Lusaka, Zambia. Immunohistochemistry was used to assess YAP-1 protein overexpression in tumor tissue relative to surrounding benign squamous epithelium. OSSN patient samples (preinvasive, n = 62, 27% and invasive, n = 165, 73%) were studied. One hundred forty-nine invasive tumors contained adjacent preinvasive tissue, bringing the total number of preinvasive lesions examined to 211 (62 + 149). There was adjacent benign squamous epithelium in 50.2% (114/227) of OSSN samples. Nuclear YAP- 1 was significantly overexpressed in preinvasive (Fisher's (F): p <.0001, Monte Carlo (MC): p <.0001) and invasive (F: p <.0001, MC: p <.0001) OSSN in comparison to adjacent benign squamous epithelium when analyzed for basal keratinocyte positive count, staining intensity, expression pattern, and Immunostaining intensity-distribution index. YAP-1 expression did not differ between preinvasive and invasive OSSN (p >.05), keratinizing and non- keratinizing cancer (p >.05), or between T1/T2 and T3/T4 stages in invasive tumors (p >.05). However, grade 2 and 3 tumors had significantly stronger nucleus YAP-1 overexpression intensity than grade 1 tumors (F: p = .0078, MC: p = .0489). By immunohistochemistry, we identified significant overexpression (upregulation of YAP-1 protein expression) in preinvasive and invasive OSSN lesions compared to neighboring benign squamous epithelium. YAP-1 expression was significantly higher in poorly and moderately differentiated invasive squamous cancer than in well-differentiated carcinomas. Overexpression of YAP-1 within the margin of preinvasive and invasive OSSN, but not in the neighboring normal epithelium, indicates that it plays a role in the development and progression of OSSN.
Identifiants
pubmed: 37476371
doi: 10.3389/fonc.2023.1213426
pmc: PMC10354641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1213426Informations de copyright
Copyright © 2023 Julius, Siyumbwa, Maate, Moonga, Kang, Kaile, West, Wood and Angeletti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eye (Lond). 2021 Jun;35(6):1562-1573
pubmed: 33564137
J Virol. 2014 Oct;88(20):12055-64
pubmed: 25122798
Genes Dev. 2019 Jul 1;33(13-14):828-843
pubmed: 31171701
Pharmacol Ther. 2018 Jun;186:60-72
pubmed: 29305295
Sci Rep. 2020 Jun 2;10(1):8916
pubmed: 32488048
Aging (Albany NY). 2019 Oct 15;11(19):8681-8700
pubmed: 31613226
Cancer Biol Med. 2017 Nov;14(4):405-413
pubmed: 29372107
PLoS One. 2012;7(3):e32783
pubmed: 22396793
Int J Cancer. 2018 Nov 1;143(9):2133-2144
pubmed: 29696628
Curr Opin Cell Biol. 2017 Dec;49:99-107
pubmed: 29316535
Pancreas. 2017 Aug;46(7):913-920
pubmed: 28697132
Pharmacol Res. 2016 Jan;103:270-8
pubmed: 26678601
Cancer Sci. 2020 Sep;111(9):3142-3154
pubmed: 32536012
Genes Cells. 2017 Jan;22(1):6-31
pubmed: 28078823
Sci Adv. 2020 Mar 18;6(12):eaay3324
pubmed: 32206709
Oral Oncol. 2018 Nov;86:25-32
pubmed: 30409308
J Contemp Dent Pract. 2019 Aug 1;20(8):887-892
pubmed: 31797842
Dev Cell. 2010 Oct 19;19(4):491-505
pubmed: 20951342
Gastric Cancer. 2018 Jul;21(4):643-652
pubmed: 29168120
Exp Ther Med. 2019 Oct;18(4):2993-3001
pubmed: 31572541
Cancer Sci. 2016 Oct;107(10):1527-1538
pubmed: 27418196
J Invest Dermatol. 2016 Jun;136(6):1267-1277
pubmed: 26902922
Oncotarget. 2017 Jan 17;8(3):4096-4109
pubmed: 27911857
Cancer Sci. 2010 May;101(5):1279-85
pubmed: 20219076
Anticancer Res. 2012 Sep;32(9):3827-34
pubmed: 22993325
Genes Dev. 2013 Feb 15;27(4):355-71
pubmed: 23431053
Int J Gynecol Cancer. 2013 May;23(4):735-42
pubmed: 23502453
Anticancer Res. 2014 Feb;34(2):811-817
pubmed: 24511017
Cell Rep. 2019 Mar 5;26(10):2636-2650.e5
pubmed: 30840887
IUBMB Life. 2019 Oct;71(10):1453-1464
pubmed: 31087779
Tumour Biol. 2013 Aug;34(4):2169-74
pubmed: 23558963
Medicine (Baltimore). 2021 Jul 16;100(28):e26597
pubmed: 34260541
Curr Ophthalmol Rep. 2021 Mar;9(1):7-15
pubmed: 34804642
PeerJ. 2020 Nov 19;8:e10397
pubmed: 33240680
Oncol Lett. 2019 Oct;18(4):3561-3570
pubmed: 31579068
Mol Cancer Res. 2015 Jun;13(6):957-68
pubmed: 25794680
Oral Oncol. 2011 Aug;47(8):693-7
pubmed: 21708480
Am J Dermatopathol. 2022 May 1;44(5):348-354
pubmed: 35234193
Cell Mol Gastroenterol Hepatol. 2021;12(4):1297-1310
pubmed: 34118488
Genes Dev. 2010 May;24(9):862-74
pubmed: 20439427
Anticancer Drugs. 2022 Apr 1;33(4):352-361
pubmed: 35266885
Bioessays. 2020 May;42(5):e1900162
pubmed: 32128850
Clin Cancer Res. 2014 Feb 15;20(4):837-46
pubmed: 24323901
Cancer. 2009 Oct 1;115(19):4576-85
pubmed: 19551889
Nat Rev Cancer. 2015 Feb;15(2):73-79
pubmed: 25592648
Int J Oncol. 2015;46(6):2364-70
pubmed: 25846049
Carcinogenesis. 2011 Mar;32(3):389-98
pubmed: 21112960
Front Oncol. 2022 Apr 14;12:864066
pubmed: 35494029
Cell Rep. 2014 Aug 7;8(3):707-13
pubmed: 25088426
Elife. 2018 Sep 20;7:
pubmed: 30231971
Expert Rev Mol Med. 2015 Jul 02;17:e14
pubmed: 26136233
Nat Rev Gastroenterol Hepatol. 2022 May;19(5):297-312
pubmed: 35064256
Ocul Oncol Pathol. 2021 Mar;7(2):108-120
pubmed: 33869164
Pharmacol Res. 2020 Sep;159:105009
pubmed: 32553712
Genes Dev. 2009 Dec 1;23(23):2729-41
pubmed: 19952108
Cell. 2015 Nov 5;163(4):811-28
pubmed: 26544935
EMBO Rep. 2014 Jun;15(6):642-56
pubmed: 24825474
Cancer Cell Int. 2021 Dec 25;21(1):705
pubmed: 34953494
Life Sci. 2018 Dec 1;214:176-183
pubmed: 30385178
Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):59-64
pubmed: 28682834
Cancer Sci. 2021 Jan;112(1):51-60
pubmed: 33159406
Oncotarget. 2017 Dec 7;9(1):668-679
pubmed: 29416644
Hum Pathol. 2008 Nov;39(11):1582-9
pubmed: 18703216
Clin Cancer Res. 2015 Jun 1;21(11):2580-90
pubmed: 25739674
FEBS Open Bio. 2019 Feb 14;9(3):437-445
pubmed: 30868052
J Cell Physiol. 2011 Apr;226(4):928-39
pubmed: 20945341
Chin Med J (Engl). 2013 Feb;126(4):655-8
pubmed: 23422184
Oncotarget. 2016 Dec 2;8(32):52333-52344
pubmed: 28881733
Oncogene. 2015 Jul;34(27):3536-46
pubmed: 25195862
EMBO Mol Med. 2015 Sep 28;7(11):1426-49
pubmed: 26417066
Nat Cell Biol. 2018 Aug;20(8):888-899
pubmed: 30050119
Int J Med Sci. 2019 May 28;16(5):766-773
pubmed: 31217745
Arch Biochem Biophys. 2021 May 15;702:108838
pubmed: 33727040
Cancer Med. 2020 Jan;9(1):259-268
pubmed: 31692299
Eye (Lond). 2023 May 31;:
pubmed: 37258660
Front Microbiol. 2021 Dec 14;12:789991
pubmed: 34970247
PLoS One. 2011;6(11):e27529
pubmed: 22096589
Cancer Res. 2020 Jul 15;80(14):3046-3056
pubmed: 32354737
Cancer Lett. 2014 Dec 28;355(2):201-9
pubmed: 25218593